bt051
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 24, 2020 (NCT05103878)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Formyl peptide receptor 1INHIBITOR
FPR1 inhibitor
ABCC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05084261 | Phase 1 | Oct 31, 2021 | Bacainn Therapeutics, Inc. |
| NCT05103878 | Phase 1 | Jun 24, 2020 | Bacainn Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bacainn Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2020 |
1 organizations
Page 1 / 1